



Universiteit  
Leiden  
The Netherlands

## **Pumping new life into preclinical pharmacokinetics: exploring the pharmacokinetic application of ex vivo organ perfusion**

Stevens, L.J.

### **Citation**

Stevens, L. J. (2024, October 29). *Pumping new life into preclinical pharmacokinetics: exploring the pharmacokinetic application of ex vivo organ perfusion*. Retrieved from <https://hdl.handle.net/1887/4106882>

Version: Publisher's Version

License: [Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden](#)

Downloaded from: <https://hdl.handle.net/1887/4106882>

**Note:** To cite this publication please use the final published version (if applicable).

# CHAPTER 02

Towards human ex vivo organ  
perfusion models to elucidate  
drug pharmacokinetics in  
health and disease

L.J. Stevens, J.M. Donkers, J. Dubbeld,  
W.H.J. Vaes, C.A.J. Knibbe, I.P.J. Alwayn\*  
E. van de Steeg\*

*\* these authors are joint senior authors*

Drug metabolism reviews, 2020

## Abstract

To predict the absorption, distribution, metabolism and excretion (ADME) profile of candidate drugs a variety of preclinical models can be applied. The ADME and toxicological profile of newly developed drugs need to be available before assessment in humans, which is associated with long time-lines and high costs. Therefore, good predictions of ADME profiles earlier in the drug development process are very valuable. Good prediction of intestinal absorption and renal and biliary excretion remain especially difficult, as there is an interplay of active transport and metabolism involved. To study these processes, including enterohepatic circulation, *ex vivo* tissue models are highly relevant and can be regarded as the bridge between *in vitro* and *in vivo* models. In this review the current *in vitro*, *in vivo* and in more detail *ex vivo* models for studying pharmacokinetics in health and disease are discussed. Additionally, we propose novel models of which we envision these will generate valuable pharmacokinetic information in the future due to improved translation to the *in vivo* situation. These machine perfused organ models will be particularly interesting when combined with biomarkers for assessing functionality of transporter and CYP450 proteins.

## 1. Introduction

Upon oral intake of a drug, intestinal absorption is the first barrier affecting the final drug concentration in the circulating blood<sup>1</sup>. Following intestinal absorption, drugs reach the liver via the portal vein, where they can be absorbed, metabolized and/or excreted into the bile. The liver is an important and complex organ, is responsible for the biotransformation of many endogenous and exogenous compounds and involved in the storage and biliary excretion of these compounds and their metabolites. In addition to the liver, extrahepatic tissues significantly contribute to the clearance of drugs as a diverse range of transporters and metabolizing enzymes have been characterized in the GI-tract and the kidneys<sup>1-5</sup>. Influx and efflux transporters, expressed on apical or basolateral membranes of these organs, and cytochrome P450 (CYP450) enzymes regulate the absorption of drugs across the intestinal wall into the portal blood, the clearance of drugs in the liver (and kidneys) and excretion by the biliary and renal pathways<sup>6</sup>. To determine how transporters and enzymes are involved with these processes is challenging as conventional research models are (too) simplified and do not properly reflect the conditions *in vivo*. For example, several studies have characterized the interplay between efflux transporter P-glycoprotein (Pgp) and CYP3A4<sup>7,8</sup>. However, knowledge about the role and contribution of transporters in biliary and renal clearance processes, the involvement of the enterohepatic cycle, and drug-drug interactions (DDI) in healthy and diseased tissues are still poorly understood.

Over the past decade, a variety of *in vitro*, *ex vivo*, *in vivo* and *in silico* preclinical models have been developed to characterize and predict absorption, distribution, metabolism and excretion (ADME) processes in the human situation. The ability to predict the ADME profile of a candidate drug in the preclinical phase is important to determine whether the drug is safe, effective and can advance to phase I clinical trials. Furthermore, the potential of the drug to interact with the kinetics of other drugs needs to be taken into account as predicting potential DDI is important for the patients health. Concomitant administration of drugs can affect the pharmacokinetic and pharmacodynamic profile of one or both compounds. This can lead to a change in the systemic exposure or site specific concentration of the drug, thereby altering the therapeutic outcome or increasing the risk of serious adverse events<sup>9-11</sup>. Extensive research regarding the potential interactions between drugs is

needed prior to clinical trials, as significant interactions can result in withdrawal of the drug from the market<sup>12</sup>. The impact on the development of new drugs in relation to DDI was shown in a systemic review by the FDA demonstrating that almost all new molecular entities had been found to be perpetrators of metabolic interactions on the basis of *in vitro* tests<sup>12,13</sup>. Therefore, it is important to study the functionality of transporters and enzymes, and their interplay in the liver, kidneys and GI tract as the most dominant organs involved in drug uptake, metabolism and excretion using proper preclinical models<sup>14</sup>. This review describes the current models and novel developments using *ex vivo* tissues to improve the predictions of human ADME profiles and DDIs.

## 2. *In vitro* and *in vivo* models for the prediction of pharmacokinetics

### *In vitro* DMPK

Multiple preclinical *in vitro* models have been developed to predict the pharmacokinetic profile and metabolic clearance of drugs. These models are mainly based on cell lines (e.g. caco-2, HEK293, MDCKII, HePaRG cells), primary cell cultures (e.g. hepatocytes), and isolated microsomes and vesicles to study organ function, drug metabolism, evaluation of transporter function and drug induced organ toxicity<sup>15</sup>. Genetically modified cell lines overexpressing a specific uptake or efflux transporter allow specific assessment of the interaction between drugs and transporter proteins. A major advantage of *in vitro* models is the possibility to study isolated processes such as phase I and II metabolism or to compare metabolism and transporter affinity across species<sup>16</sup>. The medium- to high throughput nature of *in vitro* models makes them highly attractive in drug development screening processes. However, complex processes such as transporter-enzyme interplay are difficult to evaluate *in vitro* models as transport directionality and transporter-enzyme interactions at the organ level often cannot be established<sup>8</sup>. Additionally, cell based models frequently lack specific aspects of the organ, such as the presence of and interaction between different cell types or the ability to excrete bile or urine<sup>17,18</sup>. An example of an *in vitro* model which overcomes the problem of lacking bile excretion is the sandwich-cultured hepatocyte model. The hepatocytes are cultured between two layers of collagen form canalicular networks so that hepatobiliary disposition of compounds can be studied<sup>19</sup>. A limitation of this model is the use of non-human hepatocytes leading to results that remain

difficult to translate to the human *in vivo* situation due to differences in transporter expression between species<sup>19</sup>.

### New developments in *in vitro* DMPK

Currently, the development of new predictive preclinical *in vitro* models is a field that attracts a lot of attention. The discovery of organoids, a stem-cell based 3D model derived from patient biopsy material, is generating serious attention especially in the field of disease development modelling<sup>20</sup>. Furthermore, major improvements have been established lately in conventional cell models using a combination of 3D cell models and microfluidic technology, commonly referred to as 'organ-on-a-chip' (OOC). These models incorporate microfluidics and the flow thereby generated induces shear stress and mechanical strain to the cells, with a major effect on cell adhesion, growth rate and differentiation processes<sup>21</sup>. The OOC models can better mimic the complexity of *in vivo* organs and it is expected that they will be more useful than conventional *in vitro* cell lines<sup>14,22,23</sup>. Kim et al., for example reported a gut-on-a-chip model with the incorporation of a cyclic strain mimicking peristaltic motions, important for intestinal absorption processes and the ability to co-culture with intestinal bacteria<sup>24</sup>. An advantage of OOC models is the ability to connect multiple organs cultured on a chip using microfluidics and thereby studying the interconnection between metabolizing organs. Tsamandouras et al., developed a coupled gut-liver-chip model to study PK of multiple organs and the interconnection between the organs using diclofenac and hydrocortisone. A minor but significant difference was the formation of the CYP2C diclofenac metabolite 4-OH-DCF in gut-liver chip compared to the Liver-chip alone<sup>25</sup>. Maschmeyer et al., reported a four-organ-chip including the intestine, liver, kidney and skin which is able to study ADME processes<sup>26</sup>. Although these systems are more complex compared to the conventional *in vitro* models, these systems remain cell based and as such limitations remain.

### *In vivo* animal DMPK models

To study *in vivo* processes in the preclinical phase, a variety of laboratory animal models are used. Laboratory animals are useful in different stages of drug discovery and development and are systematically used to find bioavailable compounds, compare pharmacokinetics (PK) across species, determine the no-observed-adverse-effect-level (NOAEL), test DDI potential and ensure safety<sup>27</sup>. To study the contribution of specific transporters in absorption or clearance

processes of a drug, knock-in or knock-out mouse models are often used<sup>28</sup>. However, most results obtained in pre-clinical studies using experimental animals do not translate well to the human situation<sup>29</sup>. An important contributor to this loss-in-translation is that PK processes are very different in animals and humans; i.e. the amount of drug that enters the circulation in animals shows little correlation to the relative amount measured in the blood of humans<sup>29</sup>. This is not only a result of different physiology between animals and humans, but also due to differences in transporter expression between species<sup>30</sup>. Humanized mouse models are a step towards human *in vivo* DMPK<sup>31</sup>. Katoh et al., demonstrated the metabolism of CYP2D6 substrate debrisoquin in a humanized liver mouse model and showed the presence of human albumin in the blood of the chimeric mice indicating the presence of human hepatocytes<sup>32</sup>. However the predicting intestinal absorption (or bioavailability) and renal and biliary excretion remain difficult, as there is an interplay of active transport and metabolism involved. Predicting of biliary excretion based on bile cannulation in rats or dogs often fail due to species differences<sup>18,33-35</sup>. The enterohepatic circulation (EHC) adds complexity to predicting biliary excretion. An increasing number of compounds is subjective to EHC, making it difficult to predict plasma profiles after oral or intra venous (iv) administration.

### *In vivo* human DMPK

There are limited methods to study clinical ADME processes in humans early in the drug development phase. One of these methods includes microdosing studies using a microtracer of the newly developed pharmaceutical compound labelled with [<sup>14</sup>C] radiolabel to characterize the PK of the drug using highly sensitive accelerator mass spectrometry technology<sup>36-39</sup>. There are also some unique examples of studies using human subjects undergoing surgery where it is possible to measure intestinal permeability or biliary clearance. For example, *in vivo* intestinal permeability can be assessed using a Loc-I-Gut perfusion system, placed in the jejunum where during a single-pass perfusion, the permeability of a certain compound can be studied<sup>40</sup>. To date, studying biliary excretion in humans is, up to now only possible in postsurgical patients suffering from hepatobiliary diseases and remains very challenging<sup>41</sup>.

### 3. *Ex vivo* models

By using whole or partial organs and tissues, *ex vivo* models are recognized as the bridge between *in vitro* and *in vivo* models. When studying PK and DDI in health and disease it is important that the complexity of the organ is represented in the preclinical model. It is expected that this will lead to better predictions of DMPK than predictions from more simplified, single cell type *in vitro* systems<sup>42,43</sup>. In *ex vivo* models the tissue morphology is maintained including cell-cell interactions, cell-matrix interactions, the complex efflux/uptake transporters and CYP enzyme expression. In the upcoming section the importance, advantages and limitations of existing *ex vivo* models for applications in preclinical DMPK research will be discussed (Table 2.1) (Figure 2.1).

#### 3.1. Precision cut organ slices

Precision cut organ slices (PCS) are widely used in the field of pharmacology and toxicology research<sup>43-45</sup>. It is an easy and medium throughput technique where drug metabolism in an experimental and controlled situation can be studied with the main advantage that the tissue organization and cell-cell and cell-matrix interaction is maintained<sup>18,46,47</sup>. Multiple studies show the applicability of precision cut slices for metabolic capacity assessment, drug induction, inhibition and drug transport to determine phase I and phase II metabolism and drug uptake by measuring the intracellular concentration in the slices at different time intervals<sup>48-49-51</sup>. The intestines, liver and kidneys are heterogenous organs with regional expression of transporters and enzymes in the intestine, metabolic zonation in the liver and cellular heterogeneity and structural complexity of the kidney. Therefore the PCS technique can be very useful in understanding the heterogeneity of the organ, an advantage over cellular *in vitro* systems<sup>47,52</sup>. Li et al., for example used the precision cut intestinal slices (PCIS) technique to study regional expression of Pgp and the potency of Pgp inhibitors<sup>49</sup>. Recently, Arakawa et al., studied azasetron uptake as substrate drug of efflux transporter *mdr1a* in rat kidney slices<sup>53</sup>. Additionally, increased accumulation of azasetron was measured in the presences of *mdr1* inhibitor zosuquidar showing the ability to use organ slices for DDI studies. However, whether DDI leads to a higher systemic exposure or alters biliary or renal clearance cannot be fully mimicked since the tissue is freely floating in culture medium with direct communication of intraluminal and extraluminal compartments.

Table 2.1 - Overview of the discussed ex vivo models with their advantages and disadvantages.

Model		Reference	Advantages	Disadvantages
Precision cut slices	Intestine (PCIS)	<ul style="list-style-type: none"> <li>(van de Kerkhof, de Graaf et al. 2008)</li> </ul>	<ul style="list-style-type: none"> <li>High throughput model</li> <li>Suitable for toxicity assessment</li> </ul>	<ul style="list-style-type: none"> <li>One-compartmental model; No luminal and serosal compartment</li> </ul>
	Liver (PCLS)	<ul style="list-style-type: none"> <li>(Possidente et al. 2011)</li> <li>(Renwick et al. 2000)</li> <li>(De Graaf et al. 2010)</li> <li>(Berginc et al. 2010)</li> <li>(Arakawa et al. 2017)</li> <li>(Arakawa et al. 2019)</li> </ul>	<ul style="list-style-type: none"> <li>Suitable for human and animal derived tissue</li> </ul>	<ul style="list-style-type: none"> <li>No biliary and renal excretion</li> <li>Static model</li> </ul>
	Kidney (PCKS)	<ul style="list-style-type: none"> <li>(Arakawa et al. 2019)</li> </ul>		
	Ussing Chamber	<ul style="list-style-type: none"> <li>(Sjöberg et al. 2013)</li> <li>(Rozehnal et al. 2012)</li> </ul>		
	InTESTine	<ul style="list-style-type: none"> <li>(Haslam et al. 2011)</li> <li>(Westerhout et al. 2014)</li> <li>(Stevens et al. 2019)</li> <li>(Alam et al. 2012)</li> <li>(Barthe et al. 1998)</li> <li>(Lindahl et al. 1998)</li> <li>(Gandia et al. 2004)</li> <li>(Burks and Long 1966)</li> <li>(De Vries MH et al. 1989)</li> <li>(van Midwoud et al.)</li> <li>(Dawson et al. 2016)</li> <li>(Melgert et al., 2001)</li> <li>(Schreiter et al., 2012)</li> <li>(Schreiter et al., 2016)</li> <li>(Villeneuve et al., 1996)</li> <li>(Jablonski et al., 1971)</li> <li>(Gores et al., 1986)</li> <li>(Nishiitsutsuji-Uwo et al. 1967)</li> <li>(Van Crugten et al. 1991)</li> <li>(Hori et al. 1993)</li> </ul>	<ul style="list-style-type: none"> <li>Intestinal transport from A&gt;B and B&lt;A can be assessed</li> <li>Assessment of efflux transporters using inhibition studies</li> <li>Multiple intestinal areas can be applied</li> <li>Relevant physiological morphology</li> <li>Able to study biliary and renal excretion</li> </ul>	<ul style="list-style-type: none"> <li>Static model</li> <li>Limited viability of the model, up to a maximum of 6h of incubation</li> </ul>
Perfusion models	Everted gut sac model			
	Intestine			<ul style="list-style-type: none"> <li>Difficult laboratory skills involved</li> <li>Low throughput model</li> <li>Viable for 3 – 4 hours of incubation</li> </ul>
	Liver (IPL) Lobe	Human		
	Whole liver	Animal		
	Kidney (IPK)			

Table 2.1 – (continued)

Model	Reference	Advantages	Disadvantages
Machine perfusion models	Whole Liver <ul style="list-style-type: none"><li>• (Boehnert et al., 2013)</li><li>• (De Vries et al., 2019)</li><li>• (Watson et al., 2018)</li></ul>	<ul style="list-style-type: none"><li>• Suitable for (diseased and discarded) human organs</li><li>• study biliary and renal excretion</li></ul>	<ul style="list-style-type: none"><li>• Complex surgical skills involved</li><li>• Low throughput model</li></ul>
	Kidney <ul style="list-style-type: none"><li>• (Eshmuninov et al. 2020)</li><li>• (Hosgood S et al. 2015)</li><li>• (Nicholson and Hosgood 2013)</li></ul>	<ul style="list-style-type: none"><li>• Highly translatable to <i>in vivo</i> condition</li><li>• Suitable for human (endogenous) biomarker research</li></ul>	<ul style="list-style-type: none"><li>• Limited to discarded and/or diseased human organs</li></ul>

Organ slices are widely used is still a relevant technique in the field of DMPK. Researchers use PCS to study nanoparticle formulations<sup>54,55</sup>, anticancer drugs or molecular transport mechanisms<sup>56,57</sup>. Additionally, the PCS technology and microfluidics can also be combined<sup>58,59</sup>. However, the main limitation of the model is that it is qualitative rather than quantitative as basic pharmacokinetic questions such as prediction of intestinal absorption, biliary and urinary excretion, enterohepatic circulation and the effect of DDI on these processes cannot be studied.

### 3.2. Intestinal two-compartmental models

As described in section 3.1.1., PCIS are freely floating in culture medium, so that there is no intestinal barrier between the luminal and the serosal compartment. However, to study intestinal absorption it is important to have two separate compartments. Therefore, several dual compartmental *ex vivo* methods have been developed which allow study of intestinal absorption of drugs and nutrients while maintaining barrier integrity.

#### 3.2.1. The *ussing* system

The Ussing chamber is a model in which excised mucosal intestinal tissue is mounted vertically in the system under continuously oxygenated conditions. Subsequently, vectorial transport and intestinal wall metabolism of drugs can be studied. Several studies have demonstrated the applicability of the Ussing system in determining transporter expression and the transport of different drugs including substrates for efflux transporters<sup>60-62</sup>. For instance, the presence and activity of the efflux transporter Pgp was demonstrated by incubating the Ussing system with the Pgp substrates digoxin, cimetidine, vinblastine, quinidine and verapamil, and a clear efflux effect was demonstrated for the first 4 of the 5 compounds<sup>62</sup>. Hence, the Ussing system is a useful method to predict whether newly developed drugs can affect the intestinal absorption of another compound when dosed at the same time, or if they are a substrate for efflux transporters located in the gut. Unfortunately, the model is limited by its low throughput and the difficult laboratory preparation work involved.

#### 3.2.2. *InTESTine* system

Based on the Ussing system, Westerhout et al., developed a new intestinal two-compartmental model with easier handling and higher throughput called the

InTESTine system<sup>63</sup>. In this system, segments of the mucosal intestinal layer can be mounted horizontally in a 6-well or a 24-well plate device. Smaller tissue segments and reduced apical and basolateral volumes can be used when compared to the Ussing system<sup>63-65</sup>. Using this model, CYP3A-mediated testosterone metabolism as well as the intestinal permeability of a subset of compounds was determined. Additionally, it demonstrated the suitability of the two-compartmental model to study DDI with PhIP as a BCRP substrate and elacridar as inhibitor<sup>63</sup>. Recently, the same group demonstrated the applicability of the InTESTine system with human intestinal tissue to predict the fraction absorbed ( $F_a$ ) in humans<sup>64</sup>. Besides determining the transport of a subset of compounds across the intestinal wall, regional differences in transporter activity were assessed following the regional variability in Pgp expression in ileum and mid-colon tissue. This shows the additional value of a two-compartmental intestinal model where drugs can be applied at both sides to study the interaction of the compounds at the transporter levels as well as differential expression transporters along the GI tract<sup>64</sup>.

### 3.3.3. Everted Sac method

In contrast to the Ussing and InTESTine model, the everted sac method uses whole enclosed small parts of the intestines<sup>66-68</sup>. In this model, the excised intestines are inverted, closed at both ends and placed in an oxygenated buffer. Drug metabolism, transport and the contribution of transporters in drug absorption can subsequently be studied<sup>69</sup>. Several studies showed the use of the everted sac method to determine the Pgp activity and to test compounds which are potential Pgp modifiers<sup>70</sup>. For example, Barte et al., assessed the activity of the Pgp transporter by showing an increase in digoxin transport upon co-incubation with Pgp inhibitors verapamil and quinidine<sup>71</sup>. Limitations from this model are that it is restricted to the use of animal tissue, relative large surface area and the presence of the muscularis mucosa layer which can result in an underestimation of drug transport<sup>70</sup>. While the model is very suitable for different animal species, the model is rather low throughput with difficult set-up and preparation work involved and therefore not widely applied.

## 3.4. Perfusion models

The *ex vivo* tissue models discussed thus far study the fate of a drug in a static environment. However, *in vivo* blood flow continuously stimulates cells with chemical, electrical and mechanical cues which can alter the behavior of a drug<sup>72</sup>. *Ex vivo* perfusion models make use of hemodynamics and therefore

these models are suitable to determine specific functions of the whole organ in an isolated environment in the absence of other systemic effects<sup>69</sup>. In the next section we focus on whole organ (liver and kidney) that have been developed to study biliary and renal excretion, the two most important excretion routes of drugs and tissue (intestine) perfusion models.

### *3.4.1. Intestinal perfusion models*

Multiple intestinal perfusion methods have been developed. For a long time, the incorporation of fluidics into conventional preclinical models using tissue explants has been reported by several research groups<sup>73-75</sup>. For example, the everted sac model has been developed into a perfusion model by Gandia et al.<sup>75</sup>. An advantage of using perfusion in contrast to the static everted gut sac model is that the serosal side is continuously perfused which can affect the kinetics of rapidly absorbed drugs during long term incubations. Additionally, the blood supply, intestinal tissue, innervation and clearance capabilities remain intact<sup>71,76</sup>. The isolated perfused intestine is often used to assess the effect of flow on intestinal permeability and to determine the involvement of transporters and enzymes on drug absorption<sup>77,78</sup>. Many researchers used the isolated perfused intestine technique to study CYP3A4-Pgp interplay or the specific contribution of drug transporters by using knockout animals<sup>76</sup>. A minor limitation of the perfusion technique involves the difficulty to properly measure the disappearance of a compound from the perfusion solution, especially for low permeable compounds<sup>76</sup>. Moreover, although the isolated perfused intestine is very useful for mechanistic evaluation, the limited viability of the tissue restricts the assessment of processes aside from drug transport or the assessment of transporter function<sup>79</sup>, such as host-microbe interactions and immune responses which play a significant role in gut health and barrier function but also the absorption and metabolism of drugs<sup>80</sup>. Extending the viability of the tissue would enable to study long-term exposure to drugs, intestinal absorption of low permeable drugs and the potential effects of drugs on the inflammatory state of the tissue. Here lies potential for OOC models that use fluidics to create a more physiologic relevant environment for the tissues. Although many studies show gut-on-a-chip perfusion models using single cell lines (e.g. Caco-2, HT-29 cells) or using intestinal organoids, limited gut-on-a-chip models are known using the perfusion of tissue segments. Dawson et al., showed the perfusion of Inflammatory Bowel Disease (IBD) tissue segments into an in-house developed dual-perfusion 'gut-on-a-chip-model' up to 72 hours of incubation<sup>81</sup>. Proper viability was demonstrated by the presence of the crypts

and goblet cells and also the Ki67 staining showed the proliferative capacity of the tissue after incubation. However barrier function and drug absorption was not studied. Together, these studies demonstrate the beneficial effect of fluidics on tissue viability enabling to study prolonged exposure of compounds on intestinal tissue.

### 3.4.2. Liver perfusion models

Liver perfusion models have attracted far greater attention than intestinal perfusion models. Using PCLS, various perfusion techniques have been developed; e.g. intra-tissue microneedle flow models, perfusion of the top and bottom of liver slices and flow through models<sup>82-84</sup>. The isolated perfused liver (IPL) model, a preclinical tool used to study the function of the whole liver and hepatobiliary disposition of drugs, utilizes perfusion of both the portal vein and the hepatic artery. Furthermore, IPL can be used to evaluate the physiology and pathophysiology of the liver and to study treatment of acute liver failure<sup>85</sup>. A unique aspect of the model is the close representation to the *in vivo* morphology since the 3D architecture of the tissue is maintained. The control over physiological conditions, and determining specific functions of the whole organ in an isolated environment in the absence of other systemic effects are major advantages over *in vitro* and *in vivo* studies. For example, assessment of the effect of albumin concentration on clearance processes are widely studied using the IPL model. Tsao et al studied warfarin uptake in the IPL in absence and presence of bovine serum albumin (BSA) to clarify the albumin-mediated uptake of warfarin<sup>86,87</sup>. Schary and Rowland found that unbound fraction tolbutamide varied in the perfusate upon varying concentrations of albumin or when using albumin from different species<sup>88</sup>. Shand et al., clearly showed a decrease in hepatic extraction of phenytoin upon increasing the albumin concentration from 0.5 g/dl to 5.0 g/dl<sup>89</sup>. Another physiological condition that can be controlled during perfusion is the applied flow rate. This is especially interesting since the overall hypothesis is that the clearance of drugs is related to the organ perfusion flow and the extraction ratio. Lidocaine, a high hepatic extraction ratio drug is often used as model drug in these studies showing flow dependent extraction, in comparison with the low extraction ratio drug antipyrine which is not affected by hepatic flow<sup>90</sup>. Additionally, the same researchers show in another study that the metabolite of lidocaine, MEGX, appears flow dependent. Showing that the parent drug and metabolites are in equilibrium with the concentration of the drug in the liver demonstrating that the well-stirred model describes the hepatic drug clearance<sup>90</sup>. To study the

physiology of the liver and to understand the metabolic zonation of the liver, experiments have been performed using antegrade and retrograde perfusion directions<sup>91,92</sup>. Livers from different species can be assessed where pig and rat liver are most studied. Furthermore, an advantage of the IPL compared to the *in vivo* situation is the ability to study biliary secretion which is also an important improvement to the sandwich cultured hepatocyte model<sup>18</sup>. As the interaction between two drugs may affect the biliary clearance of a drug, the IPL is an excellent model to study the effect on hepatobiliary clearance and the involvement of uptake and efflux transporters. Pfeifer et al used the IPL to demonstrate the biliary clearance of the rosuvastatin, studying the involvement of basolateral efflux transporters MRP2 and BCRP<sup>93</sup>. Using perfused livers from MRP2 deficient mice in the absence and presence of the BCRP inhibitor elacridar the researchers showed a strong reduction in rosuvastatin excretion of MRP2 deficient mice in the presence of elacridar<sup>93</sup>. Booth et al studied the concentration of Pgp substrate doxorubicin in the presence and absence of Pgp inhibitor quinidine. The biliary clearance was significantly reduced upon inhibition while perfusate and liver concentrations were not altered. The researchers also showed increased intracellular concentration of the metabolite doxorubicin thus showing the added value of using the IPL model since the perfusate, liver and biliary secretion can be studied at the same time<sup>94</sup>. The effect of enzyme-transporter interplay using the IPL was demonstrated by Lau et al., who studied the disposition of digoxin and the effect on the systemic concentration when dosed with organic anion transporting protein 1B1/1B3 (OATP1B1/OATP1B3) inhibitor rifampicin and Pgp inhibitor quinidine<sup>8</sup>. Although the IPL is a standardized and validated model, it is mainly applicable to rodents when studying drug pharmacokinetics. Furthermore, it is labor intensive, has a low throughput and the functional integrity is limited up to a few hours<sup>95</sup>. The model is still used to study liver diseases as the model includes immune cells which are involved in many liver diseases. However, it remains difficult to recapitulate the metabolic and excretion function of the liver in a chip model, therefore the IPL is still the best model<sup>23</sup>.

### 3.4.3. Isolated perfused Kidney (IPK)

Most drugs, and in particular water soluble ones, are eliminated by the kidneys and excreted by the urine<sup>96</sup>. Renal secretion involves several processes such as glomerular filtration, tubular secretion and reabsorption<sup>97</sup>. The current main preclinical kidney models (based on primary cells or cell lines) primarily focus

on the function of proximal tubuli cells. Therefore, *ex vivo* models where all main renal processes can be studied, including urinary excretion, are very valuable. Although isolated perfused kidney (IPK) is an interesting method to predict renal metabolism as well as renal clearance, only a handful of studies used the IPK model to study renal metabolism and excretion. Using IPK, Nishiitsutsji-Uwo et al., demonstrated the clearance of creatinine in the perfused rat kidney showing the function of the multidrug and toxin extrusion protein transporter 1/2K (MATE 1/2K) and the organic anion transporter (OAT)<sup>98</sup>. Although perfusion and the urinary flow remained constant, a decrease in clearance function in time was observed. Crugten et al., used the IPK technique to elucidate the renal mechanism involved in morphine clearance<sup>99</sup>. They showed the additive value of a complex whole organ model since glomerular filtration, active tubular secretion and possibly active reabsorption were processes involved in the metabolism and excretion of morphine. Besides elucidation of clearance mechanisms, also DDI can be predicted using the IPK technique. For instance, the renal tubular secretion of the Pgp substrate digoxin was shown in a study by Hori et al., where the researchers showed the dose-dependent inhibition of urinary secretion of digoxin upon co-incubation with Pgp inhibitor quinidine<sup>100</sup>.

#### 4. Novel *ex vivo* perfusion models

Although substantial relevant information regarding PK using the isolated perfused organ method has been obtained, a major limitation of the model is the short viability of 3 to 4 hours, animal origin and the decline in integrity of the perfused organs<sup>18,101</sup>. At present, there is much development in the field of organ transplantation regarding organ preservation techniques using machine perfusion. Clearly, organ preservation is of main importance, but there is also increasing interest in the viability and functional assessment of discarded donor organs which, after machine perfusion, might be used for transplantation when found to be of sufficient quality<sup>102,103</sup>. The use of pressure driven perfusion pumps allows study of the function of a whole organ under conditions that are as close as possible to the *in vivo* situation. Many studies showed viability and functionality of porcine and human livers during machine perfusion under normothermic conditions (37°C) using a red blood cell based perfusate<sup>103-106</sup> even up to 7 days<sup>107</sup>. Similar to normothermic machine perfusion (NMP) of the liver, NMP of the kidney is a method for quality assessment of extended criteria

donor kidneys<sup>108</sup>. Porcine organs are often used for method validation and device development and it is shown that normothermic machine perfusion (NMP) of organs is an excellent platform to study hepatic and renal processes<sup>109-113</sup>.

#### 4.1 Normothermic machine perfusion for DMPK research

*Ex vivo* machine perfused whole organs might be an interesting new platform to study pharmacokinetics and DDI in the liver and kidney. The commercially available pressure driven perfusion machines for kidney and liver have the ability to manually apply and adjust pressure to the artery and portal vein<sup>114,115</sup>. Adjusting the pressure will result in an altered flow through the organ and this opens the possibility to study for instance flow dependent clearance of compounds. Additionally, researchers are able to take samples from multiple locations in the circulation (e.g. portal vein and vena cava inferior) in order to study the hepatic first pass effect, or to study IV versus portal dosing and the effect of DDI. Compared to isolated perfused organ systems using rat organs or cannulated animal studies, the human or porcine machine perfusion models have relatively high circulating perfused volume (approximately 2L) and bile and urine output (approximately >10mL). This has several advantages. Collection of perfusate and urine and bile samples over time and to tissue biopsies to study intracellular accumulation is easy which makes these models ideal to study drug pharmacokinetics, metabolism, excretion and potential DDIs in a controlled setting. The applicability of machine perfusion for whole intestines is not (yet) developed, probably because intestinal transplantations are not widely performed.

#### 4.2 Opportunities involved in the perfusion of whole organs for DMPK

The major advantage of using whole organ perfusion models which are perfused with a red blood cell based perfusate is the unique opportunity to study renal and biliary excretion pathways, allowing to study more complex pharmacokinetic processes which leads to a better understanding of *in vivo* processes. Currently, research is focusing on finding novel endogenous biomarkers in bile, urine and blood which reflect the function and the status of organ-specific drug metabolizing enzymes and drug transporters<sup>116,117</sup>.

An example of such an endogenous biomarker is bilirubin, a degradation product of heme, which is transported by the hepatic Organic Anion

Transporting Protein 1B1 (OATP1B1) and OATP1B3 into the liver. In the liver, bilirubin is conjugated to bilirubin glucuronide by UGT1A1 and subsequently excreted by MRP2 in the bile or by MRP3 in the blood. This means that potential interaction of drugs with OATP1B1 and/or -1B3 transporter can be assessed by measuring the unconjugated bilirubin concentration in the blood. As OATP1B1 and OATP1B3 are involved in the clearance of a variety of drugs by the liver, applying an endogenous biomarker reflecting the function of these transporters is of major value<sup>118</sup>. The conjugated bilirubin concentration in the bile is reflecting the involvement of MRP2 while conjugated bilirubin in the blood is a biomarker for MRP3. In contrast to the IPL where often radiolabel [<sup>3</sup>H] bilirubin is used to measure bilirubin in a limited volume, a recent study by Eshmuminov et al., showed the bilirubin levels in the plasma and bile of perfused livers without using [<sup>3</sup>H] bilirubin<sup>107</sup>. Thereby showing proper OATP1B1/1B3 function during perfusion of the livers. Additionally, coproporphyrin I (CPI) and III (CPIII) (byproduct of the heme synthesis), dehydroepiandrosterone sulfate, conjugated and unconjugated bile acids and fatty acid dicarboxylates can function also as biomarker of OATP1B1 and -1B3 function<sup>116,118,119</sup>. The application of endogenous biomarkers as a useful tool to study transporter involvement in clinical trials was demonstrated by Jones et al.,<sup>120</sup>. The researchers measured the endogenous biomarker CPI and CPIII in a clinical study to elucidate the involvement of OATP1 transporters for DDI of fenebrutinib with midazolam, simvastatin and rosuvastatin<sup>120</sup>. As CPI and CPIII concentrations remained unchanged upon fenebrutinib administration the researchers concluded the observed DDI was due to involvement of CYP3A and BCRP rather than the OATP1B transporters. Likewise, different endogenous biomarkers for transporter functionality have been established for the kidney: hippurate and taurine (for transporter OAT1), 6B-hydroxycortisol (OAT3), thiamine (OCT/MATE1/2K), tryptophan (OCT2) and creatinine (MATE1/2K and OCT2). Besides endogenous biomarkers for transporter function it is found that 4B-hydroxycholesterol (4βHC) is an endogenous metabolite formed by the major hepatic metabolizing enzyme CYP3A4, thus functioning as a marker for CYP3A4 functioning<sup>118</sup>. In a clinical study by Kasichayanula et al., it was shown that upon administration of ketoconazole, an inhibitor of CYP3A4, 4βHC decreased. Subsequently upon administration of rifampicin, increased 4βHC was measured<sup>121</sup>. Endogenous biomarkers can play a significant role in organ perfusion as the biomarkers reflect the condition of the organ during perfusion. The ability to administer victim and perpetrator drugs in a controlled setting and the easy accession to plasma, bile and urine lead to valuable

pharmacokinetic and DDI knowledge. On the other hand, organ perfusion models can contribute to the validation of endogenous biomarkers e.g. the inhibition of specific transporters and studying the effect of a compound on the biomarker profile. Additionally, perfusion models can play a major role by the identification of new endogenous biomarkers.

Moreover, the novel perfusion machines with incorporated pressure, temperature and flow sensors can also be a major advantage for the field of advanced physiologically based pharmacokinetic modelling (PBPK) modeling. PBPK models are mathematical multicompartmental models where assumptions based generated in *in vitro* and also *ex vivo* models regarding transporter abundance, metabolizing enzymes and biliary and urinary excretion are made to predict the clearance of a drug<sup>122,123</sup>. Using these assumptions, simulated profiles are generated and subsequently validated with *in vivo* animal studies to see whether PBPK models match the *in vivo* data. The incorporation of experimental data derived from perfused organs into advanced PBPK models can be highly interesting. Clearance, excretion processes, intracellular concentrations, CYP enzymes and transporter expression can all be determined. At the same time, flow settings can be controlled. Of special interest for PBPK modelling are diseased organs since it is known that in liver disease for instance, different processes as the hepatic blood flow, CYP enzymes and transporter expression are altered as well as changes in liver and renal function<sup>122</sup>.

## 5. Application of *ex vivo* models in disease

Accurate predictions in diseased patients remain difficult as proper preclinical models for human diseases are often lacking. It would be a major advantage if diseased human tissues could be used earlier in the drug development process to assess disease-specific drug efficacy and safety. The challenge of using human tissue is the donor-to-donor variability and differences in disease status. However, this can be seen as an advantage since the use of *ex vivo* models is a step closer to the *in vivo* situation and thus a better prediction of *in vivo* DMPK processes. To measure the disease status or quality of the organs, endogenous biomarkers can play a role. This is currently widely applied in the field of organ transplantation using biomarkers in the bile, urine and blood as quality assessment of perfused organs<sup>103,106</sup>.

### *Ex vivo* models in intestinal disease

Inflammatory bowel disease (IBD), which includes ulcerative colitis and Crohn's disease, is a group of intestinal diseases showing increased prevalence numbers<sup>124</sup>. It is reported that the expression of certain transporters is altered in the inflamed intestinal regions of patients suffering from IBD<sup>125,126</sup>. For example, it was shown that in mice with intestinal inflammation, Pgp transporter expression and activity was reduced<sup>127</sup>. Interestingly, in the non-inflamed regions an increased activity of Pgp was detected, showing a possible compensatory mechanism in the intestines. Using inflammatory and non-inflammatory regions from IBD patients, the application of PCIS or tissue segments mounted in a two-compartmental setting can be helpful to determine the  $F_a$  of compounds, the effect of drug substrates for certain (efflux) transporters, DDI and the potential altered effect on first-pass metabolism. On the other hand, when specific drugs in the treatment for IBD need to be tested, an intestinal perfusion model using dual fluidics would be crucial to assess the effect of immune modulating drugs on the inflamed intestinal tissue as a longer incubation period is needed and thus extended viability of the tissue needs to be guaranteed.

### *Ex vivo* models in liver disease

Altered hepatobiliary transporter expression as well as affected CYP expression are found in patients suffering from liver diseases such as cirrhosis, nonalcoholic steatohepatitis and primary sclerosing cholangitis<sup>128-130</sup>. This may drastically affect drug treatment and drug efficacy in these patients. The use of PCLS of diseased human liver tissue generated useful information regarding the altered metabolic capacity of the diseased liver<sup>131</sup>. Additionally, using human fibrotic tissue in PCLS has proven to be beneficial when studying potential antifibrotic drugs, DDI and drug induced liver injury (DILI) in fibrotic liver tissue<sup>131</sup>. Despite the fact that perfusion models can be very informative and unravel underlying mechanisms in liver disease, the perfusion of the isolated liver is only limitedly used for studying liver diseases using rodent livers as liver diseases need to be induced. Promising models include diet-induced (genetically modified) murine models of non-alcoholic steatohepatitis, reflecting the key inflammatory and cirrhotic processes involved<sup>132,133</sup>.

Machine perfusion of redundant whole human organs would be the holy grail, but obviously the use of this technology for pharmacokinetic application is hampered by the availability of healthy human donor organs. There are

however opportunities when applying this technology (or machine perfusion) to 'diseased' organs which, following a pathological assessment are currently discarded after transplantation. Studying the pathophysiology of diseased livers using human orthotopic tissue is particularly helpful as animal models and human disease remains difficult to compare, however limited studies evaluated PK processes of these redundant human organs. Villeneuve et al., described the use of perfused whole human cirrhotic livers to study drug disposition and metabolism in diseased livers as one of the first<sup>134,135</sup>. Their research showed that the application of diseased liver in a perfusion setting is very useful in studying the clearance function of the liver in healthy and diseased state<sup>134</sup>. As very little is known regarding the uptake of drugs in humans and especially in cirrhotic patients, studying site-specific delivery of drugs in an isolated environment of the other organs is of additional value<sup>136</sup>. Melgert et al., and Schreiter et al., studied the functionality of a liver lobe and resected tissue of cirrhotic and non-cirrhotic livers while being perfused under normothermic conditions. Melgert et al., showed phase I and phase II metabolism of lidocaine and 7-hydroxycoumarin in the liver lobe perfusion model<sup>136</sup>, while Schreiter et al., compared the metabolic activity of resected tissue of cirrhotic livers to non-cirrhotic livers<sup>137</sup>. The metabolism of paracetamol, midazolam and diclofenac, metabolized by CYP1A1, CYP3A4 or CYP2C9 respectively, was studied and showed that cirrhotic resected tissue had diminished and slower phase I and phase II transformation of those drugs compared to non-cirrhotic tissue<sup>137</sup>. The same researchers demonstrated acetaminophen-induced liver injury of resected liver tissue as they were able to keep the tissue viable up to 30 hours by making use of NMP. Thereby they show the potential of using diseased perfused livers for the pharmacokinetic application and prolongation of the viability of resected tissue<sup>138</sup>.

### *Ex vivo* models in kidney disease

A kidney disease affecting kidney function is polycystic kidney disease (PKD). Patients develop fluid-filled cysts in their kidneys which can affect the PK of drugs. Besides altered kidney function, PKD can also affect other organs like the liver and thereby altering liver transporter expression and function<sup>139</sup>. A case report from 1988 described the association of liver cysts with polycystic kidney disease (PKD) and the relation to MRP2 function<sup>140</sup>. Although the use of human tissue is preferred in the prediction of drug metabolism, the use of animal models can be useful in understanding the development of disease processes or the effect of diseases on the function of other metabolic organs. Benzeçon

et al., used the IPL model using PKD induced rats to determine the effect of PKD on hepatic transporter function and biliary excretion which in this case showed to be a very suitable model for this disease<sup>139</sup>. On the other hand, in patients with liver disease compensatory mechanisms in extrahepatic tissues were observed as a result of the reduced hepatic elimination of drugs. For example, it was studied in humans *in vivo* as well as in rat models that with end-stage liver disease the transporters OATP1 and OATP2 were upregulated in the kidney<sup>141</sup>. This renal compensation mechanism was also found for the clearance of N-methylnicotinamide, which was related to the severity of liver cirrhosis<sup>142</sup>. As a consequence, increased renal exposure can result in a higher risk for renal DDI and drug induced injury showing the difficulty *in vivo* to study DMPK in diseased tissues. Another effect of kidney disease is that it might affect the plasma protein concentration and the ability of plasma proteins to bind to drugs, resulting in a higher unbound fraction of the circulating drug<sup>143</sup>. Kidney machine perfusion models not only create the possibility to assess the functionality of the organ and study the involvement of transporters, also different perfusate compositions can be tested and subsequently the effect on plasma protein binding can be assessed in an experimental environment.

## 6. Conclusion

This review provides an overview of available experimental predictive models to study drug absorption, metabolism and excretion processes, as well as DDI, in health and disease. The use of *ex vivo* models to predict pharmacokinetics has shown to be very useful and valuable considering the intact morphology and presence of the metabolizing enzymes and transporters in the tissue. A diverse range of *ex vivo* models are nowadays available, each with their own advantages and limitations. Maintenance of the viability and integrity of the tissue is a major challenge observed for every model and tissue type. With increasing complexity also more complicated problems and challenges arise as more factors and unknown processes are involved. However, these complex models are expected to provide better translatability to the *in vivo* situation. The multifactorial and complex development of disease is often not fully characterized and therefore make it a huge challenge to properly predict pharmacokinetic processes in diseased patients. This indicates that improved preclinical models remain needed to generate reliable translational results for both healthy and diseased patients.

## References

1. Shitara Y, Sato H, Sugiyama Y. Evaluation of drug-drug interaction in the hepatobiliary and renal transport of drugs. *Annu Rev Pharmacol Toxicol*. 2005;45:689-723.
2. Müller F, Fromm MF. Transporter-mediated drug-drug interactions. *Pharmacogenomics* 2011;12:1017-1037.
3. van de Steeg E, Stránecký V, Hartmannová H, Nosková L, Hřebíček M, Wagenaar E, van Esch A, et al. Complete OATP1B1 and OATP1B3 deficiency causes human Rotor syndrome by interrupting conjugated bilirubin reuptake into the liver. *The Journal of clinical investigation* 2012;122:519-528.
4. Chan LM, Lowes S, Hirst BH. The ABCs of drug transport in intestine and liver: efflux proteins limiting drug absorption and bioavailability. *European journal of pharmaceutical sciences* 2004;21:25-51.
5. Krishna DR, Klotz U. Extrahepatic metabolism of drugs in humans. *Clinical pharmacokinetics* 1994;26:144-160.
6. Kusuhara H, Sugiyama Y. Role of transporters in the tissue-selective distribution and elimination of drugs: transporters in the liver, small intestine, brain and kidney. *Journal of Controlled Release* 2002;78:43-54.
7. Benet L, Cummins C, Wu C. Unmasking the dynamic interplay between efflux transporters and metabolic enzymes. *International journal of pharmaceutics* 2004;277:3-9.
8. Lau YY, Wu C-Y, Okochi H, Benet LZ. Ex situ inhibition of hepatic uptake and efflux significantly changes metabolism: hepatic enzyme-transporter interplay. *Journal of Pharmacology and Experimental Therapeutics* 2004;308:1040-1045.
9. Rowland M, Benet LZ, Graham GG. Clearance concepts in pharmacokinetics. *Journal of pharmacokinetics and biopharmaceutics* 1973;1:123-136.
10. Singh SS. Preclinical pharmacokinetics: an approach towards safer and efficacious drugs. *Current drug metabolism* 2006;7:165-182.
11. Fagerholm U. Prediction of human pharmacokinetics—biliary and intestinal clearance and enterohepatic circulation. *Journal of Pharmacy and Pharmacology* 2008;60:535-542.
12. Palatini P, De Martin S. Pharmacokinetic drug interactions in liver disease: An update. *World journal of gastroenterology* 2016;22:1260.
13. Yu J, Ritchie TK, Mulgaonkar A, Ragueneau-Majlessi I. Drug disposition and drug-drug interaction data in 2013 FDA new drug applications: a systematic review. *Drug Metabolism and Disposition* 2014;42:1991-2001.
14. Zhu J. Application of Organ-on-Chip in Drug Discovery. *Journal of Biosciences and Medicines* 2020;8:119-134.
15. Li AP. Human hepatocytes: isolation, cryopreservation and applications in drug development. *Chemico-biological interactions* 2007;168:16-29.
16. Lipscomb JC, Poet TS. In vitro measurements of metabolism for application in pharmacokinetic modeling. *Pharmacology & therapeutics* 2008;118:82-103.
17. Fabre G, Combalbert J, Berger Y, Cano J-P. Human hepatocytes as a key in vitro model to improve preclinical drug development. *European journal of drug metabolism and pharmacokinetics* 1990;15:165-171.
18. Guillouzo A. Liver cell models in in vitro toxicology. *Environmental health perspectives* 1998;106:511-532.
19. Swift\* B, Pfeifer\* ND, Brouwer KL. Sandwich-cultured hepatocytes: an in vitro model to evaluate hepatobiliary transporter-based drug interactions and hepatotoxicity. *Drug metabolism reviews* 2010;42:446-471.
20. Sato T, Clevers H. Growing self-organizing mini-guts from a single intestinal stem cell: mechanism and applications. *Science* 2013;340:1190-1194.
21. Yum K, Hong SG, Healy KE, Lee LP. Physiologically relevant organs on chips. *Biotechnology journal* 2014;9:16-27.

22. Bhise NS, Ribas J, Manoharan V, Zhang YS, Polini A, Massa S, Dokmeci MR, et al. Organ-on-a-chip platforms for studying drug delivery systems. *Journal of Controlled Release* 2014;190: 82-93.
23. Fowler S, Chen K, Duignan D, Gupta A, Hariparsad N, Kenny JR, Lai G, et al. Microphysiological Systems for ADME-Related Applications: Current Status and Recommendations for System Development and Characterization. *Lab on a Chip*. 2020;20(3):446-467..
24. Kim HJ, Huh D, Hamilton G, Ingber DE. Human gut-on-a-chip inhabited by microbial flora that experiences intestinal peristalsis-like motions and flow. *Lab on a Chip* 2012;12:2165-2174.
25. Tsamandouras N, Chen WLK, Edington CD, Stokes CL, Griffith LG, Cirit M. Integrated gut and liver microphysiological systems for quantitative in vitro pharmacokinetic studies. *The AAPS journal* 2017;19:1499-1512.
26. Maschmeyer I, Lorenz AK, Schimek K, Hasenberg T, Ramme AP, Hübner J, Lindner M, et al. A four-organ-chip for interconnected long-term co-culture of human intestine, liver, skin and kidney equivalents. *Lab on a Chip* 2015;15:2688-2699.
27. Zhang D, Luo G, Ding X, Lu C. Preclinical experimental models of drug metabolism and disposition in drug discovery and development. *Acta Pharmaceutica Sinica B* 2012;2:549-561.
28. van de Steeg E, Wagenaar E, van der Kruijsen CM, Burggraaff JE, de Waart DR, Elferink RPO, Kenworthy KE, et al. Organic anion transporting polypeptide 1a/1b-knockout mice provide insights into hepatic handling of bilirubin, bile acids, and drugs. *The Journal of clinical investigation* 2010;120.
29. Shanks N, Greek R, Greek J. Are animal models predictive for humans? *Philosophy, ethics, and humanities in medicine* 2009;4:2.
30. Wendler A, Wehling M. The translatability of animal models for clinical development: biomarkers and disease models. *Current opinion in pharmacology* 2010;10:601-606.
31. Ito R, Takahashi T, Katano I, Ito M. Current advances in humanized mouse models. *Cellular & molecular immunology* 2012;9:208-214.
32. Katoh M, Sawada T, Soeno Y, Nakajima M, Tateno C, Yoshizato K, Yokoi T. In vivo drug metabolism model for human cytochrome P450 enzyme using chimeric mice with humanized liver. *Journal of pharmaceutical sciences* 2007;96:428-437.
33. Ito K, Iwatsubo T, Kanamitsu S, Ueda K, Suzuki H, Sugiyama Y. Prediction of pharmacokinetic alterations caused by drug-drug interactions: metabolic interaction in the liver. *Pharmacological reviews* 1998;50:387-412.
34. Musther H, Olivares-Morales A, Hatley OJ, Liu B, Hodgejegan AR. Animal versus human oral drug bioavailability: do they correlate? *European Journal of Pharmaceutical Sciences* 2014;57: 280-291.
35. Lentz KA. Current methods for predicting human food effect. *The AAPS journal* 2008;10: 282-288.
36. Lappin G, Noveck R, Burt T. Microdosing and drug development: past, present and future. *Expert opinion on drug metabolism & toxicology* 2013;9:817-834.
37. Mooij MG, van Duijn E, Knibbe CA, Allegaert K, Windhorst AD, van Rosmalen J, Hendrikse NH, et al. Successful Use of [14 C] Paracetamol Microdosing to Elucidate Developmental Changes in Drug Metabolism. *Clinical pharmacokinetics* 2017;56:1185-1195.
38. Swart P, Lozac'h F, Simon M, van Duijn E, Vaes WH. The impact of early human data on clinical development: there is time to win. *Drug discovery today* 2016;21:873-879.
39. van Groen BD, Vaes WH, Park BK, Krekels EH, van Duijn E, Körgvee LT, Maruszak W, et al. Dose-linearity of the pharmacokinetics of an intravenous [14C] midazolam microdose in children. *British journal of clinical pharmacology* 2019;85:2332-2340.
40. Lennernäs H. Animal data: the contributions of the Ussing Chamber and perfusion systems to predicting human oral drug delivery in vivo. *Advanced drug delivery reviews* 2007;59: 1103 1120.
41. Ghibellini G, Leslie EM, Brouwer KL. Methods to evaluate biliary excretion of drugs in humans: an updated review. *Molecular pharmaceutics* 2006;3:198-211.
42. Benet L, Cummins C, Wu C. Transporter-enzyme interactions: implications for predicting drug-drug interactions from in vitro data. *Current drug metabolism* 2003;4:393-398.

43. Vickers AE, Fisher RL. Precision-cut organ slices to investigate target organ injury. *Expert opinion on drug metabolism & toxicology* 2005;1:687-699.
44. Baverel G, Knouzy B, Gauthier C, El Hage M, Ferrier B, Martin G, Duplany A. Use of precision-cut renal cortical slices in nephrotoxicity studies. *Xenobiotica* 2013;43:54-62.
45. Troth SP, Simutis F, Friedman GS, Todd S, Sistare FD. Kidney Safety Assessment: Current Practices in Drug Development. In: *Seminars in nephrology*; 2019: Elsevier; 2019. p. 120-131.
46. De Graaf IA, Olinga P, De Jager MH, Merema MT, De Kanter R, Van De Kerkhof EG, Groothuis GM. Preparation and incubation of precision-cut liver and intestinal slices for application in drug metabolism and toxicity studies. *Nature protocols* 2010;5:1540.
47. Parrish AR, Gandolfi AJ, Brendel K. Precision-cut tissue slices: applications in pharmacology and toxicology. *Life sciences* 1995;57:1887-1901.
48. Renwick AB, Watts PS, Edwards RJ, Barton PT, Guyonnet I, Price RJ, Tredger JM, et al. Differential maintenance of cytochrome P450 enzymes in cultured precision-cut human liver slices. *Drug Metabolism and Disposition* 2000;28:1202-1209.
49. Li M, de Graaf IA, Groothuis GM. Precision-cut intestinal slices: alternative model for drug transport, metabolism, and toxicology research. *Expert opinion on drug metabolism & toxicology* 2016;12:175-190.
50. Possidente M, Dragoni S, Franco G, Gori M, Bertelli E, Teodori E, Frosini M, et al. Rat intestinal precision-cut slices as an in vitro model to study xenobiotic interaction with transporters. *European Journal of Pharmaceutics and Biopharmaceutics* 2011;79:343-348.
51. van de Kerkhof EG, de Graaf IA, Ungell A-LB, Groothuis GM. Induction of metabolism and transport in human intestine: validation of precision-cut slices as a tool to study induction of drug metabolism in human intestine in vitro. *Drug Metabolism and Disposition* 2008;36: 604-613.
52. Kanter R, Monshouwer M, Meijer D, Groothuis G. Precision-cut organ slices as a tool to study toxicity and metabolism of xenobiotics with special reference to non-hepatic tissues. *Current drug metabolism* 2002;3:39-59.
53. Arakawa H, Kubo H, Washio I, Staub AY, Nedachi S, Ishiguro N, Nakanishi T, et al. Rat Kidney Slices for Evaluation of Apical Membrane Transporters in Proximal Tubular Cells. *Journal of pharmaceutical sciences* 2019.
54. Bartucci R, Åberg C, Melgert BN, Boersma YL, Olinga P, Salvati A. Time-Resolved Quantification of Nanoparticle Uptake, Distribution, and Impact in Precision-Cut Liver Slices. *Small* 2020;19:06523.
55. Daga M, de Graaf IA, Argenziano M, Barranco ASM, Loeck M, Al-Adwi Y, Cucci MA, et al. Glutathione-responsive cyclodextrin-nanosponges as drug delivery systems for doxorubicin: Evaluation of toxicity and transport mechanisms in the liver. *Toxicology in Vitro* 2020;65:104800.
56. Estrada-Ortiz N, Guarra F, de Graaf IA, Marchetti L, de Jager MH, Groothuis GM, Gabbiani C, et al. Anticancer Gold N-Heterocyclic Carbene Complexes: A Comparative in vitro and ex vivo Study. *ChemMedChem* 2017;12:1429-1435.
57. Spreckelmeyer S, Estrada-Ortiz N, Prins GG, Van Der Zee M, Gammelgaard B, Stürup S, De Graaf IA, et al. On the toxicity and transport mechanisms of cisplatin in kidney tissues in comparison to a gold-based cytotoxic agent. *Metallomics* 2017;9:1786-1795.
58. Meekel JP, Groeneveld ME, Bogunovic N, Keekstra N, Musters RJ, Zandieh-Doulabi B, Pals G, et al. An in vitro method to keep human aortic tissue sections functionally and structurally intact. *Scientific reports* 2018;8:1-12.
59. Rodriguez AD, Horowitz LF, Castro K, Kenerson H, Bhattacharjee N, Gandhe G, Raman A, et al. A microfluidic platform for functional testing of cancer drugs on intact tumor slices. *Lab on a Chip* 2020;20(9):1658-1675.
60. Haslam IS, O'Reilly DA, Sherlock DJ, Kauser A, Womack C, Coleman T. Pancreatoduodenectomy as a source of human small intestine for Ussing chamber investigations and comparative studies with rat tissue. *Biopharmaceutics & drug disposition* 2011;32:210-221.

61. Rozehnal V, Nakai D, Hoepner U, Fischer T, Kamiyama E, Takahashi M, Yasuda S, et al. Human small intestinal and colonic tissue mounted in the Ussing chamber as a tool for characterizing the intestinal absorption of drugs. *European Journal of Pharmaceutical Sciences* 2012;46:367-373.
62. Sjöberg Å, Lutz M, Tannergren C, Wingolf C, Borde A, Ungell A-L. Comprehensive study on regional human intestinal permeability and prediction of fraction absorbed of drugs using the Ussing chamber technique. *European Journal of Pharmaceutical Sciences* 2013;48:166-180.
63. Westerhout J, van de Steeg E, Grossouw D, Zeijdner EE, Krul CA, Verwei M, Wortelboer HM. A new approach to predict human intestinal absorption using porcine intestinal tissue and biorelevant matrices. *European Journal of Pharmaceutical Sciences* 2014;63:167-177.
64. Stevens LJ, van Lipzig MM, Erpelinck SL, Pronk A, van Gorp J, Wortelboer HM, van de Steeg E. A higher throughput and physiologically relevant two-compartmental human ex vivo intestinal tissue system for studying gastrointestinal processes. *European Journal of Pharmaceutical Sciences* 2019;137:104989.
65. Vaessen SF, van Lipzig MM, Pieters RH, Krul CA, Wortelboer HM, van de Steeg E. Regional expression levels of drug transporters and metabolizing enzymes along the pig and human intestinal tract and comparison with Caco-2 cells. *Drug Metabolism and Disposition* 2017;45:353-360.
66. Bridges JF. A study of macromolecule absorption in vitro by the small intestine of adult rats: Keele University; 1980.
67. Levine RR, McNary WF, Kornguth PJ, LeBlanc R. Histological reevaluation of everted gut technique for studying intestinal absorption. *European journal of pharmacology* 1970;9:211-219.
68. Wilson TH, Wiseman G. The use of sacs of everted small intestine for the study of the transference of substances from the mucosal to the serosal surface. *The Journal of physiology* 1954;123:116-125.
69. Roeselers G, Ponomarenko M, Lukovac S, Wortelboer HM. Ex vivo systems to study host-microbiota interactions in the gastrointestinal tract. *Best Practice & Research Clinical Gastroenterology* 2013;27:101-113.
70. Alam MA, Al-Jenoobi FI, Al-mohizea AM. Everted gut sac model as a tool in pharmaceutical research: limitations and applications. *Journal of Pharmacy and Pharmacology* 2012;64:326-336.
71. Barthe L, Bessouet M, Woodley J, Houin G. The improved everted gut sac: a simple method to study intestinal P-glycoprotein. *International journal of pharmaceutics* 1998;173:255-258.
72. Bhadriraju K, Chen CS. Engineering cellular microenvironments to improve cell-based drug testing. *Drug discovery today* 2002;7:612-620.
73. Burks T, Long J. 5-Hydroxytryptamine release into dog intestinal vasculature. *American Journal of Physiology-Legacy Content* 1966;211:619-625.
74. De Vries MH, Rademaker CM, Geerlings C, Van Duk A, Noordhoek J. Pharmacokinetic modelling of the effect of activated charcoal on the intestinal secretion of theophylline, using the isolated vascularly perfused rat small intestine. *Journal of Pharmacy and Pharmacology* 1989;41:528-533.
75. Gandia P, Lacombe O, Woodley J, Houin G. The perfused everted intestinal segment of rat. *Arzneimittelforschung* 2004;54:467-473.
76. Stappaerts J, Brouwers J, Annaert P, Augustijns P. In situ perfusion in rodents to explore intestinal drug absorption: challenges and opportunities. *International journal of pharmaceutics* 2015;478:665-681.
77. Prasad N, Bhasker S. Characterization of intestinal transport of Vincristine in rats applying in situ single pass intestinal perfusion. *Pharmacologia* 2012;3:617-621.
78. Schanker LS, Tocco DJ, Brodie BB, Hogben CAM. Absorption of drugs from the rat small intestine. *Journal of Pharmacology and Experimental Therapeutics* 1958;123:81-88.
79. Maeng HJ, Durk MR, Chow EC, Ghoneim R, Pang KS. 1 $\alpha$ , 25-Dihydroxyvitamin D3 on intestinal transporter function: studies with the rat everted intestinal sac. *Biopharmaceutics & drug disposition* 2011;32:112-125.

80. van de Steeg E, Schuren FH, Obach RS, van Woudenberg C, Walker GS, Heerikhuisen M, Nooijen IH, et al. An ex vivo fermentation screening platform to study drug metabolism by human gut microbiota. *Drug Metabolism and Disposition* 2018;46:1596-1607.
81. Dawson A, Dyer C, Macfie J, Davies J, Karsai L, Greenman J, Jacobsen M. A microfluidic chip based model for the study of full thickness human intestinal tissue using dual flow. *Biomicrofluidics* 2016;10:064101.
82. Schumacher K, Khong Y-M, Chang S, Ni J, Sun W, Yu H. Perfusion culture improves the maintenance of cultured liver tissue slices. *Tissue engineering* 2007;13:197-205.
83. van Midwoud PM, Merema MT, Verpoorte E, Groothuis GM. Perfusion of Human Precision-Cut Liver Slices in a Microfluidic Device for Metabolism and Toxicology Studies. An alternative approach based on microfluidics to study drug metabolism and toxicity using liver and intestinal tissue:101.
84. Khong YM, Zhang J, Zhou S, Cheung C, Doberstein K, Samper V, Yu H. Novel intra-tissue perfusion system for culturing thick liver tissue. *Tissue engineering* 2007;13:2345-2356.
85. Jablonski P, Douglas M, Gordon E, Owen J, McK. Watts J. Studies on the isolated perfused pig liver. *British Journal of Surgery* 1971;58:129-137.
86. Tsao SC, Sugiyama Y, Sawada Y, Iga T, Hanano M. Kinetic analysis of albumin-mediated uptake of warfarin by perfused rat liver. *Journal of pharmacokinetics and biopharmaceutics* 1988;16:165-181.
87. Stollman YR, Gärtner U, Theilmann L, Ohmi N, Wolkoff AW. Hepatic bilirubin uptake in the isolated perfused rat liver is not facilitated by albumin binding. *The Journal of clinical investigation* 1983;72:718-723.
88. Schary WL, Rowland M. Protein binding and hepatic clearance: studies with tolbutamide, a drug of low intrinsic clearance, in the isolated perfused rat liver preparation. *Journal of pharmacokinetics and biopharmaceutics* 1983;11:225-243.
89. Shand DG, Cotham RH, Wilkinson GR. Perfusion-limited effects of plasma drug binding on hepatic drug extraction. *Life sciences* 1976;19:125-130.
90. Pang KS, Rowland M. Hepatic clearance of drugs. I. Theoretical considerations of a "well-stirred" model and a "parallel tube" model. Influence of hepatic blood flow, plasma and blood cell binding, and the hepatocellular enzymatic activity on hepatic drug clearance. *Journal of pharmacokinetics and biopharmaceutics* 1977;5:625-653.
91. O'Sullivan D, Brosnan TJ, Brosnan EM. Hepatic zonation of the catabolism of arginine and ornithine in the perfused rat liver. *Biochemical Journal* 1998;330:627-632.
92. Pang KS, Koster H, Halsema I, Scholtens E, Mulder GJ, Stillwell R. Normal and retrograde perfusion to probe the zonal distribution of sulfation and glucuronidation activities of harmol in the perfused rat liver preparation. *Journal of Pharmacology and Experimental Therapeutics* 1983;224:647-653.
93. Pfeifer ND, Yang K, Brouwer KL. Hepatic basolateral efflux contributes significantly to rosuvastatin disposition I: characterization of basolateral versus biliary clearance using a novel protocol in sandwich-cultured hepatocytes. *Journal of Pharmacology and Experimental Therapeutics* 2013;347:727-736.
94. Booth CL, Brouwer KR, Brouwer KL. Effect of multidrug resistance modulators on the hepatobiliary disposition of doxorubicin in the isolated perfused rat liver. *Cancer research* 1998;58:3641-3648.
95. Bessems M, 't Hart N, Tolba R, Doorschodt B, Leuvenink H, Ploeg R, Minor T, et al. The isolated perfused rat liver: standardization of a time-honoured model. *Laboratory animals* 2006;40:236-246.
96. Bekersky I. Use of the isolated perfused kidney as a tool in drug disposition studies. *Drug metabolism reviews* 1983;14:931-960.
97. Van Ginneken C, Russel F. Saturable pharmacokinetics in the renal excretion of drugs. *Clinical pharmacokinetics* 1989;16:38-54.
98. Nishiitsutsuji-Uwo J, Ross B, Krebs H. Metabolic activities of the isolated perfused rat kidney. *Biochemical Journal* 1967;103:852.

99. Van Crugten JT, Sallustio BC, Nation RL, Somogyi AA. Renal tubular transport of morphine, morphine-6-glucuronide, and morphine-3-glucuronide in the isolated perfused rat kidney. *Drug metabolism and disposition* 1991;19:1087-1092.
100. Hori R, Okamura N, Aiba T, Tanigawara Y. Role of P-glycoprotein in renal tubular secretion of digoxin in the isolated perfused rat kidney. *Journal of Pharmacology and Experimental therapeutics* 1993;266:1620-1625.
101. Gores GJ, Kost LJ, Larusso NF. The isolated perfused rat liver: conceptual and practical considerations. *Hepatology* 1986;6:511-517.
102. Vogel T, Brockmann JG, Friend PJ. Ex-vivo normothermic liver perfusion: an update. *Current opinion in organ transplantation* 2010;15:167-172.
103. Watson CJ, Kosmoliaptsis V, Pley C, Randle L, Fear C, Crick K, Gimson AE, et al. Observations on the ex situ perfusion of livers for transplantation. *American Journal of Transplantation* 2018;18:2005-2020.
104. Boehnert M, Yeung J, Bazerbach F, Knaak J, Selzner N, McGilvray I, Rotstein O, et al. Normothermic acellular ex vivo liver perfusion reduces liver and bile duct injury of pig livers retrieved after cardiac death. *American Journal of Transplantation* 2013;13:1441-1449.
105. Borie DC, Eyraud D, Boleslawski E, Lemoine A, Sebah M, Cramer DV, Roussi J, et al. Functional metabolic characteristics of intact pig livers during prolonged extracorporeal perfusion: potential for a unique biological liver-assist device. *Transplantation* 2001;72:393-405.
106. de Vries Y, Matton AP, Nijsten MW, Werner MJ, van den Berg AP, de Boer MT, Buis CI, et al. Pretransplant sequential hypo-and normothermic machine perfusion of suboptimal livers donated after circulatory death using a hemoglobin-based oxygen carrier perfusion solution. *American Journal of Transplantation* 2019;19:1202-1211.
107. Eshmuminov D, Becker D, Borrego LB, Hefti M, Schuler MJ, Hagedorn C, Muller X, et al. An integrated perfusion machine preserves injured human livers for 1 week. *Nature Biotechnology* 2020;1-10.
108. Hosgood S, Barlow A, Hunter J, Nicholson M. Ex vivo normothermic perfusion for quality assessment of marginal donor kidney transplants. *British Journal of Surgery* 2015;102:1433-1440.
109. Butler AJ, Rees MA, Wight DG, Casey ND, Alexander G, White DJ, Friend PJ. Successful extracorporeal porcine liver perfusion for 72 hr1. *Transplantation* 2002;73:1212-1218.
110. Yoshikawa R, Matsuno N, Morito N, Gouchi M, Otani M, Takahashi H, Shonaka T, et al. Evaluation Using an Isolated Reperfusion Model for Porcine Liver Donated After Cardiac Death Preserved with Oxygenated Hypothermic Machine Perfusion. *Annals of transplantation* 2018;23:822.
111. Jamieson RW, Zilvetti M, Roy D, Hughes D, Morovat A, Coussios CC, Friend PJ. Hepatic steatosis and normothermic perfusion—preliminary experiments in a porcine model. *Transplantation* 2011;92:289-295.
112. Hosgood SA, van Heurn E, Nicholson ML. Normothermic machine perfusion of the kidney: better conditioning and repair? *Transplant International* 2015;28:657-664.
113. Vogel T, Brockmann JG, Pigott D, Neil DA, Muthusamy ASR, Coussios CC, Friend PJ. Successful transplantation of porcine liver grafts following 48-hour normothermic preservation. *PloS one* 2017;12:e0188494.
114. OrganAssist. n.d. [accessed]. <https://www.organ-assist.nl/products/liver-assist/>.
115. Organox. n.d. [accessed]. <https://www.organox.com/>.
116. Rodrigues A, Taskar K, Kusuvara H, Sugiyama Y. Endogenous probes for drug transporters: balancing vision with reality. *Clinical Pharmacology & Therapeutics* 2018;103:434-448.
117. Fromm M. Prediction of Transporter-Mediated Drug-Drug Interactions Using Endogenous Compounds. *Clinical Pharmacology & Therapeutics* 2012;92:546-548.
118. Chu X, Chan GH, Evers R. Identification of endogenous biomarkers to predict the propensity of drug candidates to cause hepatic or renal transporter-mediated drug-drug interactions. *Journal of pharmaceutical sciences* 2017;106:2357-2367.

119. Shen H, Dai J, Liu T, Cheng Y, Chen W, Freeden C, Zhang Y, et al. Coproporphyrins I and III as functional markers of OATP1B activity: in vitro and in vivo evaluation in preclinical species. *Journal of Pharmacology and Experimental Therapeutics* 2016;357:382-393.
120. Jones NS, Yoshida K, Salphati L, Kenny JR, Durk MR, Chinn LW. Complex DDI by Fenebrutinib and the Use of Transporter Endogenous Biomarkers to Elucidate the Mechanism of DDI. *Clinical Pharmacology & Therapeutics* 2020;107:269-277.
121. Kasichayanula S, Boulton DW, Luo WL, Rodrigues AD, Yang Z, Goodenough A, Lee M, et al. Validation of 4 $\beta$ -hydroxycholesterol and evaluation of other endogenous biomarkers for the assessment of CYP3A activity in healthy subjects. *British journal of clinical pharmacology* 2014;78:1122-1134.
122. Jones H, Rowland-Yeo K. Basic concepts in physiologically based pharmacokinetic modeling in drug discovery and development. *CPT: pharmacometrics & systems pharmacology* 2013;2:1-12.
123. Fleishaker JC, Smith RB. Compartmental model analysis in pharmacokinetics. *The Journal of Clinical Pharmacology* 1987;27:922-926.
124. Bilski J, Mazur-Bialy A, Wojcik D, Surmiak M, Magierowski M, Sliwowski Z, Pajdo R, et al. Role of Obesity, Mesenteric Adipose Tissue, and Adipokines in Inflammatory Bowel Diseases. *Biomolecules* 2019;9:780.
125. Blokzijl H, Borghot SV, Bok LI, Libbrecht L, Geuken M, Van den Heuvel FA, Dijkstra G, et al. Decreased P-glycoprotein (P-gp/MDR1) expression in inflamed human intestinal epithelium is independent of PXR protein levels. *Inflammatory bowel diseases* 2007;13:710-720.
126. Blokzijl H, Van Steenpaal A, Vander Borghot S, Bok LI, Libbrecht L, Tamminga M, Geuken M, et al. Up-regulation and cytoprotective role of epithelial multidrug resistance-associated protein 1 in inflammatory bowel disease. *Journal of Biological Chemistry* 2008;283:35630-35637.
127. Buyse M, Radeva G, Bado A, Farinotti R. Intestinal inflammation induces adaptation of P-glycoprotein expression and activity. *Biochemical pharmacology* 2005;69:1745-1754.
128. Czerwinski M, Oberheide B, Hatfield N, Ewy B, Seib C, Gatineau E, Yiannikouris F, et al. Microsomal cytochrome P450 enzyme activities in nonalcoholic steatohepatitis livers. In: *Drug Metabolism and Pharmacokinetics*; 2019: JAPANESE SOC STUDY XENOBIOTICS INT MED INF CENTER SHINANOMACHI RENGAKAN, 35 ...; 2019. p. S25-S25.
129. George J, Murray M, Byth K, Farrell GC. Differential alterations of cytochrome P450 proteins in livers from patients with severe chronic liver disease. *Hepatology* 1995;21:120-128.
130. Zollner G, Fickert P, Silbert D, Fuchsbichler A, Marschall H-U, Zatloukal K, Denk H, et al. Adaptive changes in hepatobiliary transporter expression in primary biliary cirrhosis. *Journal of hepatology* 2003;38:717-727.
131. Westra IM. Precision-cut liver slices: an ex vivo model for the early onset and end-stage of liver fibrosis: Rijksuniversiteit Groningen, 2014.
132. Morrison MC, Kleemann R, van Koppen A, Hanemaaijer R, Verschuren L. Key inflammatory processes in human NASH are reflected in Ldlr $^{-/-}$ . Leiden mice: a translational gene profiling study. *Frontiers in physiology* 2018;9:132.
133. Abe N, Kato S, Tsuchida T, Sugimoto K, Saito R, Verschuren L, Kleemann R, et al. Longitudinal characterization of diet-induced genetic murine models of non-alcoholic steatohepatitis with metabolic, histological, and transcriptomic hallmarks of human patients. *Biology open* 2019;8:bio041251.
134. Villeneuve JP, Huet PM, Gariepy L, Fenyves D, Willems B, Côté J, Lapointe R, et al. Isolated perfused cirrhotic human liver obtained from liver transplant patients: a feasibility study. *Hepatology* 1990;12:257-263.
135. Villeneuve J-P, Dagenais M, Huet P-M, Lapointe R, Roy A, Marleau D. Clearance by the liver in cirrhosis. III. Propranolol uptake by the isolated perfused human liver. *Canadian journal of physiology and pharmacology* 1996;74:1327-1332.
136. Melgert BN, Olinga P, Weert B, Slooff MJ, Meijer DK, Poelstra K, Groothuis GM. Cellular distribution and handling of liver-targeting preparations in human livers studied by a liver lobe perfusion. *Drug metabolism and disposition* 2001;29:361-367.

137. Schreiter T, Marquitan G, Darnell M, Sowa J-P, Bröcker-Preuss M, Andersson TB, Baba HA, et al. An ex vivo perfusion system emulating in vivo conditions in noncirrhotic and cirrhotic human liver. *Journal of Pharmacology and Experimental Therapeutics* 2012;342:730-741.
138. Schreiter T, Sowa J-P, Schlattjan M, Treckmann J, Paul A, Strucksberg K-H, Baba HA, et al. Human ex-vivo liver model for acetaminophen-induced liver damage. *Scientific reports* 2016;6:31916.
139. Bezençon J, Beaudoin JJ, Ito K, Fu D, Roth SE, Brock WJ, Brouwer KL. Altered Expression and Function of Hepatic Transporters in a Rodent Model of Polycystic Kidney Disease. *Drug Metabolism and Disposition* 2019;47:899-906.
140. Salam M, Keeffe EB. Liver cysts associated with polycystic kidney disease: role of Tc-99m hepatobiliary imaging. *Clinical nuclear medicine* 1989;14:803-807.
141. Wang L, Zhou M-T, Chen C-Y, Yin W, Wen D-X, Cheung C-W, Yang L-Q, et al. Increased renal clearance of rocuronium compensates for chronic loss of bile excretion, via upregulation of Oatp2. *Scientific reports* 2017;7:40438.
142. Orlando R, Floreani M, Napoli E, Padrini R, Palatini P. Renal clearance of N1-methylnicotinamide: A sensitive marker of the severity of liver dysfunction in cirrhosis. *Nephron* 2000;84:32-39.
143. Reidenberg MM, Odar-Cederlöf I, von Bahr C, Borgå O, Sjöqvist F. Protein binding of diphenylhydantoin and desmethylinipramine in plasma from patients with poor renal function. *New England Journal of Medicine* 1971;285:264-267.

